Gene Therapy: A Primer for Radiologists

Radiographics

Volumn 18, Issue 6, 1998, Pages 1343-1372

  Voss, Stephan D ^a   Kruskal, Jonathan B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chromosomes; Familial conditions; Genes and genetics; Neoplasms, therapy, ** .30 2

Indexed keywords

COMBINED IMMUNODEFICIENCY; CYSTIC FIBROSIS; GENE THERAPY; GENE VECTOR; GRAFT OCCLUSION; HUMAN; INTERVENTIONAL RADIOLOGY; METHODOLOGY; NEOPLASM; PERIPHERAL VASCULAR DISEASE; REVIEW;

CYSTIC FIBROSIS; GENE THERAPY; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; NEOPLASMS; PERIPHERAL VASCULAR DISEASES; RADIOLOGY, INTERVENTIONAL; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0032197566     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiographics.18.6.9821189     Document Type: Article

References (63)

1. Haseltine WA. Discovering genes for new medicines. Sci Am 1997; 276:92-97.
2. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature 1970; 226:1209-1211.
3. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970; 226:1211-1213.
4. Mullis KB. The unusual origin of the polymerase chain reaction. Sci Am 1990; 262:56-61, 64-65.
5. Culver KW. Gene therapy: a handbook for physicians. Larchmont, NY: Mary Ann Liebert, 1994.
6. Boulikas T. Cancer gene therapy and immunotherapy. Int J Oncol 1996; 9:941-954.
7. Boulikas T. Gene therapy to human diseases. Int J Oncol 1996; 9:1239-1251.
8. Brandt ML. Gene therapy in pediatric surgery. Semin Pediatr Surg 1996; 5:197-205.
9. Panis Y, Kienmanesh-Rad AR, Boyer O, et al. Gene therapy for liver tumors. Surg Oncol Clin North Am 1996; 5:461-473.
10. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89:21-39.
11. Tuting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. J Mol Med 1997; 75:478-491.
12. Voss SD, Hong R, Sondel PM. Severe combined immunodeficiency, interleukin-2, and the IL-2 receptor: experiments of nature continue to point the way. Blood 1994; 83:626-635.
13. Riordan JF, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073.
14. Wilson JM. Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 1995; 96:2547-2554.
15. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334:1185-1187.
16. Hug H. Fas-mediated apoptosis in tumor formation and defense. Biol Chem 1997; 378:1405-1412.
17. Rowan S, Fisher DE. Mechanisms of apoptotic cell death. Leukemia 1997; 11:457-465.
18. Krontiris TG. Molecular medicine: oncogenes. N Engl J Med 1995; 333:303-306.
19. Harris CC. Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88:1442-1455.
20. Arai H, Gordon D, Nabel EG, et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997; 94:13862-13867.
21. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2:985-991.
22. Skuse GR, Ludlow JW. Tumor suppressor genes in disease and therapy. Lancet 1995; 345:902-906.
23. Ehrlich P. The collected papers of Paul Ehrlich. Vol 2. London, England: Pergamon, 1956; 561-562.
24. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5:153-164.
25. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-182.
26. Pardoll DM. Paracrine cytokine adjuvants in cancer and immunotherapy. Annu Rev Immunol 1995; 13:399-415.
27. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4:328-332.
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a systemic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4:321-327.
29. Mahvi DM, Sondel PM, Yang NS, et al. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 1997; 8:875-891.
30. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-3543.
31. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10:180-199.
32. Guinan EC, Gribbon JG, Boussiotis VA, et al. Pivotal role of the B7/CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84:3261-3282.
33. Boussiotis VA, Lee BJ, Freeman GJ, et al. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas-and Bax-mediated programmed cell death. J Immunol 1997; 159:3156-3167.
34. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15:341-349.
35. Nabel GJ, Gordon D, Bishop DK, et al. Transfer of allogeneic major histocompatibility complex and beta-2 microglobulin genes with DNA liposome complexes in human melanoma (abstr). Proc Am Soc Clin Oncol 1996; 15:A575.
36. Freeman SM, Whartenby KA, Freeman JL, et al. In-situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23:31-45.
37. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91:8302-8306.
38. Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the bystander effect: a cytokine cascade. Exp Hematol 1996; 24:829-838.
39. Caruso M, Pham-Nguyen K, Xu B, et al. Adenovirus mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996; 93:11302-11306.
40. Chen CH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastases of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995; 92:2577-2581.
41. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348:370-374.
42. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996; 272:689-693.
43. Isner JM, Walsh K, Rosenfield K, et al. Clinical protocol: arterial gene therapy for restenosis. Hum Gene Ther 1996; 7:989-1011.
44. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265:781-784.
45. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993; 362: 801-809.
46. Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995; 92:1137-1141.
47. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to lung. Hum Gene Ther 1996; 7:1701-1717.
48. Daemen T, Velinova M, Regts J, et al. Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology 1997; 26:416-423.
49. Woodle MC, Newman MS, Working PK. Biological properties of sterically stabilized liposomes. In: Lasic D, Martin F, eds. Stealth liposomes. Boca Raton, Fla: CRC Press, 1995; 103-117.
50. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotech 1995; 13:527-537.
51. Cooper MJ. Noninfectious gene transfer and expression systems for cancer gene therapy. Semin Oncol 1996; 23:172-187.
52. Wolff JA, Malone R, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-1468.
53. Blau HM, Springer ML. Muscle mediated gene therapy. N Engl J Med 1995; 333:1554-1556.
54. Mahvi DM, Burkholder JK, Turner J, et al. Particle-mediated gene transfer of granulocyte-macrophage colony stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996; 7:1535-1543.
55. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263:14621-14624.
56. Buchsbaum DJ, Raben D, Stackhouse MA, et al. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Therapy 1996; 3:1042-1068.
57. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med 1995; 1: 786-791.
58. Weissleder R, Simonova M, Bogdanova A, et al. MR imaging and scintigraphy of gene expression through melanin induction. Radiology 1997; 204:425-429.
59. Koretsky A. NMR detection of the consequences of transgene expression. News Physiol Sci 1994; 9:197-202.
60. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56:4087-4095.
61. Kruskal JB, Cay O. Hepatic in vivo video microscopy: a useful technique for evaluating liver tumor growth, blood supply, and experimental anticancer therapies. Biotech Int 1997; 1:279-289.
62. Cay O, Kruskal JB, Nasser I, Thomas P, Clouse ME. Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin. Radiology 1997; 205:95-101.
63. U.S. Congress Office of Technology Assessment. Mapping our genes: the Human Genome Projects - how big, how fast? Publication QTA-BA-373. Washington, DC: Government Printing Office, 1988.